Ting Zhao, Michelle Tew, Talitha Feenstra, Pieter van Baal, Michael Willis, William J.
Valentine, Philip M. Clarke, Barnaby Hunt, James Altunkaya, An Tran-Duy, Richard F.
Pollock, Samuel J. P. Malkin, Andreas Nilsson, Phil McEwan, Volker Foos, Jose Leal, Elbert
S. Huang, Neda Laiteerapong, Mark Lamotte, Harry Smolen, Jianchao Quan, Luís
Martins, Mafalda Ramos & Andrew J. Palmer. The Impact of Unrelated Future Medical
Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Applied Health
Economics and Health Policy. https://doi.org/10.1007/s40258-024-00914-z.
Mafalda Ramos, Laetitia Gerlier, Anastasia Uster, Louise Muttram, Dominik Steubl,
Andrew H Frankel, Mark Lamotte. Development and Validation of a Chronic Kidney
Disease Progression Model Using Patient-Level Simulations. Renal Failure (IRNF)
https://doi.org/10.1080/0886022X.2024.2406402
Altunkaya J, Li X, Adler A, Feenstra T, Fridhammar A, Keng MJ, Lamotte M, McEwan P,
Nilsson A, Palmer AJ, Quan J, Smolen H, Tran-Duy A, Valentine W, Willis M, Leal J, Clarke
P, Examining the impact of structural uncertainty across ten type 2 diabetes models:
Results from the 2022 Mount Hood Challenge, Value in Health (2024), doi:
https://doi.org/10.1016/j.jval.2024.06.010.
Pavol Kral, Thomas Holst-Hansen, Anamaria V. Olivieri, Cristina Ivanescu, Mark
Lamotte, Sara Larsen. The Correlation Between Body Mass Index and Health-Related
Quality of Life: Data from Two Weight-Loss Intervention Studies. Advances in Therapy
2024. ADTH-D-24-00217R2. DOI: 10.1007/s12325-024-02932-8
Ichiro Tatsuno, Laetitia Gerlier, Anamaria-Vera Olivieri, James Baker-Knight, Mark
Lamotte. Assessing the health and economic burden of obesity-related complications in
East-Asian populations: implementation of risk equations in the Core Obesity Model for
Japan and model validation. Accepted by BMJ Public Health on May 22 2024.
Mafalda Ramos , Laetitia Gerlier, Anastasia Uster, Louise Muttram, Andrew H. Frankel,
Mark Lamotte. Cost-effectiveness of empagliflozin as add-on to standard of care for
chronic kidney disease management in the United Kingdom. Journal of Medical
Economics (IJME) 2024. https://doi.org/10.1080/13696998.2024.2357041
Silva Miguel L, Soares M, Olivieri A, Sampaio F, Lamotte M, Shukla S, Conde V, Freitas
P, Costa J, Borges M. Cost-effectiveness of semaglutide 2.4 mg in chronic weight
management in Portugal. Diabetol Metab Syndr. 2024 Apr 30;16(1):97. doi:
10.1186/s13098-024-01338-4.
Michael F. Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte,
Laetitia Gerlier, Howard Thom. The Cost-Effectiveness of a Bimekizumab
Versus IL-17A inhibitors Treatment-Pathway in Patients with Active Axial
Spondyloarthritis in Scotland Journal of Medical Economics 2024:
https://doi.org/10.1080/13696998.2024.2342209
Mohammed AlHarbi, Abdullah Othman, Ahmed Ali Nahari, Ahmed Hamdan Al-Jedai,
Daniel Cuadras, Faisal Almalky, Fayez AlAzmi, Hajer Yousef Almudaiheem, Hamad
AlShubrumi, Hameed AlSwat, Homaid AlSahafi, Kamelia Sindi, Khadija Basaikh, Majed
AlQahtani, Mark Lamotte , Moataz Yahia, Mohamed El-Khedr Hassan, Mohammed
AlMutlaq, Mohammed AlRoaly, Somaya AlZelaye, Zein AlGhamdi. Burden of Illness of
Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study.
Adv Ther. 2024 Jan 19. doi: 10.1007/s12325-023-02772-y.
2023
chan k, hansen k, muratov s, khoudigian s, lamotte m. smart connected insulin dose monitoring
technologies versus soc: a canadian cost-effectiveness analysis. accepted for publication in journal
of comparative effectiveness research on december 18 (2023) e230124 10.57264/cer-2023-0124.
olivieri av, muratov s, larsen s, luckevich m, chan k, lamotte m, lau dcw. cost-effectiveness of
weight-management pharmacotherapies in canada: a societal perspective. accepted for publication
in international journal of obesity on december 15 2023.
joseph e. biskupiak, mafalda ramos, carol j. levy, greg forlenza, colin hopley, jennifer boyd,
dan swift, mark lamotte, diana i brixner. cost-effectiveness of the tubeless automated insulin
delivery system versus standard of care in the management of type 1 diabetes in the united
states. j manag care spec pharm. 2023;29(6):1-11.
2022
richard j. auchus, carine courtillot, adrian dobs, diala el-maouche, henrik falhammar, andre
lacroix, mallory farrar, conor o'donoghue, milena anatchkova, katelyn cutts, natalie taylor, chuck
yonan, mark lamotte, philippe touraine. treatment patterns and unmet needs in adults with
classic congenital adrenal hyperplasia: a modified delphi consensus study. frontiers in
endocrinology, 13:1005963 doi 10.3389/fendo.2022.1005963
ehlers lh, lamotte m, ramos m, sandgaard s, holmgaard p, kristensen mm, ejskjaer n. the cost-
effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on
metformin alone in denmark. diabetes therapy.
v. manteigas, l. martins, j. cruz, m. fonseca, a.p. jesus. erya-bulk and erya-profiling: an
application for quantitative pige analysis. computer physics communications, 2022; 275: 108307.
2021
michelle tew, michael willis, christian asseburg, andreas nilsson, an tran-duy, mark lamotte,
mafalda ramos, lei si, hui shao, lizheng shi, ping zhang, phil mcewan, wen ye, william h.
herman, shihchen kuo, chunting yang, deanna isaman, wendelin schramm, fabian sailer, alan
brennan, laura heathcote, daniel pollard, chloe thomas, harry j. smolen, james gahn, rishi
patel, josé leal, alastair gray, talitha feenstra, andrew j. palmer, philip clarke. exploring structural
uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic
simulation models: findings from the ninth mount hood diabetes quality-of-life challenge. medical
decision making 2021. 1-13
jendle j, eeg-olofsson k, svensson am, franzen s, lamotte m, levrat-guillen f. cost-
effectiveness of the freestyle libre ® system versus blood glucose self-monitoring in individuals with
type 2 diabetes on insulin treatment in sweden. diabetes therapy 2021
.
jendle j, eeg-olofsson k, svensson am, franzen s, lamotte m, levrat-guillen f. cost-
effectiveness of the freestyle libre system versus self-monitoring of blood glucose in people with
type 2 diabetes on insulin treatment not reaching glycemic goals in sweden. accepted for poster
presentation at american diabetes association's (ada's) 81st scientific sessions. poster presentation
number 135-lb.
ehlers lh, lamotte m, ramos m, sandgaard s, holmgaard p, frary ec, ejskjaer n. the cost-
effectiveness of oral semaglutide versus empagliflozin in type 2 diabetes in denmark. journal of
comparative effectiveness research 2021. doi: 10.2217/cer-2021-0169.
mccrimmon rj, lamotte m, ramos m, alsaleh ajo, souhami e, lew e. cost-effectiveness of
iglarlixi versus ideglira in type 2 diabetes mellitus inadequately controlled by glp-1 receptor
agonists and oral antihyperglycemic therapy. diabetes therapy 2021
.
ramos m, men p, wang x, ustyugova a, lamotte m. cost-effectiveness of empagliflozin in patients
with type 2 diabetes and established cardiovascular disease in china. cost ef resour alloc (2021)
19:46 .
owusu-ofori s, sekongo ym, rajab ja, asamoah-akuoko l, magutu v, bah a, lamotte m, dierick
k. health economic value of blood in kenya, ghana and ivory coast: the case of maternal bleeding.
africa sanguine 2021; vol 23: number 1.
salem a, hu h, ramos m, zhong h, lamotte m. potential clinical and economic impact of optimised
maintenance therapy on discharged copd patients after hospitalisation for an exacerbation in china.
bmj open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664.
cai r, gerlier l, eichner m, schwehm m, majaram s, mould-quevedo j, lamotte m. cost-
effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza
vaccine in germany. journal of medical economics 2021.
ehlers lh, lamotte m, monteiro s, sandgaard s, holmgaard p, frary ec, ejskjaer n. the cost-
effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and
established cardiovascular disease. diabetes therapy
lopes s, meincke hh, lamotte m, olivieri ava, lean m. a novel decision model to predict the impact
of weight management interventions: the core obesity model. obesity science & practice 2021.
nuno marques, laetitia gerlier, mafalda ramos, helder pereira, sérgia rocha, ana catarina
fonseca, ana andré, ricardo melo, eduard sidelnikov. patient and caregiver productivity loss and
indirect costs associated with cardiovascular events in portugal. perda de produtividade e custos
indiretos de doentes e cuidadores associados a eventos cardiovasculares em portugal. revista
portuguesa de cardiologia. 2021.40 (2): 109-115
martindale c.s, ramos m, roberti g, roberts p, taylor k, sacks g. multicenter prospective
evaluation of parenteral nutrition preparation time and resource utilization: 3-chamber bags
compared with hospital pharmacy-compounded bags. jpen j parenter enteral nutr. 2021
sep;45(7):1552-1558.
l. martins, p. amaro, s. pessanha, m. guerra, j. machado, m. l. carvalho. j. p. santos and p.
indelicato. overview and calculation of x-ray k-shell transition yields for comprehensive data libraries.
x-ray spectrometry. 2020; 49:398-423.
2020
salem a, men p, ramos m, zhang yj, ustyugova a, lamotte m. cost-effectiveness analysis of
empagliflozin compared to glimepiride in patients with type 2 diabetes in china. journal of
comparative effectiveness research 2021.
ramos m, cummings hm, ustyugova a, raza is, de silva su, lamotte m. long-term cost-
effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the
treatment of type 2 diabetes in the uk. diabetes therapy 2020; 11(9), 2041-2055;
.
lopes s, johansen p, lamotte m, mcewan p, olivieri av, foos v. external validation of the core
obesity model to assess the cost effectiveness of weight management interventions.
pharmacoeconomics 2020.
lopes s, johansen p, lamotte m, mcewan p, olivieri av, foos v.authors' reply to comment on
"external validation of the core obesity model to assess the cost-effectiveness of weight
management interventions". pharmacoeconomics. 2021 jan;39(1):137-138. doi: 10.1007/s40273-
020-00982-8. epub 2020 nov 30.
ramos m, ustyugova a, hau n, lamotte m. the cost-effectiveness of empagliflozin
compared to liraglutide based on cardiovascular outcome trials in type 2
diabetes. journal of comparative effectiveness research 2020. /li>
si l, willis ms, asseburg c, tew m, clarke pm, lamotte m, ramos m, hui s, shi l, zhang p,
mcewan p, ye w, herman wh, isaman dj, kuo s, schramm w, sailer f, brennan a, pollard d,
smolen hj, leal j, gray a, patel r, feenstra t, palmer aj. evaluating the ability of economic models
of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth mount hood
diabetes challenge. value in health 2020.
2019
ramos m, foos v, ustyugova a, hau n, gandhi p, lamotte m. cost-effectiveness analysis of
empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in
patients with type 2 diabetes and established cardiovascular disease. diabetes therapy 2019.
kent s, becker f, feenstra t, tran-duy a, schlackow i, tew m, zhang p, ye w, lizheng s, herman
w, mcewan p, schramm w, gray a, leal j, lamotte m, palmer a, willis m, clarke p. the challenge
of transparency and validation in health economic decision modelling: a view from the mountain top.
pharmacoeconomics 2019.
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, amarenco p, annemans l patient and
caregiver productivity loss and indirect costs associated with cardiovascular events in europe.
european journal of preventive cardiology. doi: 10.1177/2047487319834770.
lau e, salem a, chan jcn, so wy, lim mct, ngai w, kong a, lamotte m, luk a. insulin glargine
compared to neutral protamine hagedorn (nph) insulin in patients with type-2 diabetes
uncontrolled with oral anti-diabetic agents alone in hong kong: a cost-effectiveness analysis. cost
effectiveness and resource allocation 2019.
goodall g, lamotte m, ramos m, maunoury f, pejchalova b, de pouvourville g. cost-effectiveness
analysis of the sapien 3 tavi valve compared with surgery in intermediate-risk patients. j med
economics 2019. 2019, vol. 22, no. 4, 289-296.
ramos m, lamotte m, gerlier l, svangren p, miquel-casas a, haughney j. the cost-effectiveness
of physical activity in the management of copd patients in the uk. international journal of copd
2019:14 227-239.
2018
foos v, wang k, mcewan p, zhang y, xin p, jiang x, qu s, xiong t, de moor r, ramos m, lamotte
m, ji l. assessing the burden of type 2 diabetes in china considering the current status-quo
management and implications of improved management using a modeling approach. value in health
regional issues. volume 18, may 2019, pages 36-46.
rodríguez-zapeda m, gonzález l, bravo a, pompa t, silva s, paredes r, garcía j, ramos m,
wikinson l, lamotte m. cost-effectiveness of rfviia versus pd-apcc in the management of mild to
moderate bleeds in pediatric patients with hemophilia a with inhibitors in mexico. value health reg
issues. 2018 oct 11;17:164-173. doi: 10.1016/j.vhri.2018.06.007.
s pinar bilir, richard hellmund, elizabeth wehler, huimin li, julie munakata, mark lamotte. the
cost-effectiveness of a flash glucose monitoring system for management of patients with type 2
diabetes receiving intensive insulin treatment in sweden. european endocrinology,
2018;14(2):80-5.
s pinar bilir, richard hellmund, elizabeth wehler, huimin li, julie munakata, mark lamotte. cost-
effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes
receiving intensive insulin treatment in sweden. european endocrinology, 2018;14(2):73-9.
palmer aj, si l, tew m, hua x, willis ms, asseburg c, mcewan p, leal j, gray a, foos v, lamotte
m, feenstra t, o'connor pj, brandle m, smolen hj, gahn jc, valentine wj, pollock rf, breeze p,
brennan a, pollard d, ye w, herman wh, isaman dj, kuo s, laiteerapong n, tran-duy a, clarke p.
computer modeling of diabetes and its transparency: a report on the eighth mount hood
challenge. value in health 2018.
l. martins, p. amaro, s. pessanha, m. guerra, j. machado, m. l. carvalho, and j. p. santos.
multiconfiguration dirac-fock calculations of zn k-shell radiative and nonradiative transitions. x-ray
spectrometry. 2019; 49:192-199.
s. pessanha, s. silva, l. martins, j. p. santos, and j. m. silveira, suitability of the compton-to-
rayleigh ratio in x-ray fluorescence spectroscopy: hydroxyapatite-based materials characterization.
journal of analytical atomic spectrometry. 2019; 34(5):854-859
2017
decuypere f, sermon j, geerts p, denee tr, de vos c, malfait b, lamotte m, mulder cl. treatment
continuation of four long-acting antipsychotic medications in the netherlands and belgium: a
retrospective database study. plos one. 2017 jun 14;12(6):e0179049. doi:
10.1371/journal.pone.0179049. ecollection 2017.
gerlier l, lamotte m, grenèche s, lenne x, carrat f, weil-olivier c, damm o, schwehm m, eichner
m. assessment of public health and economic impact of intranasal live-attenuated influenza
vaccination of children in france using a dynamic transmission model. appl health econ health
policy. 2017 apr;15(2):261-276. doi: 10.1007/s40258-016-0296-4.
p. amaro, j. p. santos, a. samouco, r. adão, l. martins, s. weber, s. tashenov, m. l. carvalho, s.
pessanha. validation of the geant4 monte carlo package for x-ray fluorescence spectroscopy in
triaxial geometry. spectrochimica acta part b: atomic spectroscopy. 2017; 130:60-66
m, fonseca, r. mateus, c. santos, j. cruz, h. silva, h. luis, l. martins, a. p. jesus. quantitative
analysis of li by pige technique. nuclear instruments and methods in physics research section b:
beam interactions with materials and atoms. 2017; 406:144-147
2016
gerlier l, lamotte m, dos santos mendes s, damm o, schwehm m, eichner m. estimates of the
public health impact of a paediatric vaccination programme using an intranasal tetravalent live-
attenuated influenza vaccine in belgium. paediatr drugs. 2016 jun 7.pp 1-16. doi 10.1007/s40272-
016-0180-6.
de francesco m, lamotte m, ascierto pa, di rienzo p, asukai y. economic evaluation of ipilimumab
in first line treatment of advanced melanoma in italy. global & regional health technology
assessment. doi: 10.5301/grhta.5000230.
ramos m, haughney j, henry n, lindner l, lamotte m. the cost-utility of aclidinium bromide
400μg/formoterol fumarate dihydrate 12μg compared to aclidinium bromide 400μg alone in the
management of moderate to severe chronic obstructive pulmonary disease. clinicoeconomics and
outcomes research 2016:8 445-456.
m. streicher, v. corregidor, n. catarino, l.c. alves, n. franco, m. fonseca, l. martins, e. alves,
e.m. costa, b.a. dedavid. study of in distribution on gainsb: al crystals by ion beam techniques.
nuclear instruments and methods in physics research section b: beam interactions with materials
and atoms. 2016; 371:278-282.
2015
de francesco m, ronco c, wacinski pj, wessely r, hernández p, lamotte m. economic impact of
contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast
media in germany, italy, poland and spain. the journal of medical economics.
chevalier p, vandebrouck t, de keyzer d, mertens a, lamotte m. cost and co-morbidities
associated with hypoglycemic inpatients in belgium. the journal of medical economics, august 2015
doi: 10.3111/13696998.2015.1086775
jugrin av, ustyugova a, urbich m, de francesco m, lamotte m, sunderland t. indirect comparison
and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended
anticoagulation of venous thromboembolism in a uk setting. the journal of medical economics,
august 2015. doi: 10.3111/13696998.2015.1078340.
jugrin av, ustyugova a, urbich m, lamotte m, sunderland t. the cost-utility of dabigatran etexilate
compared with warfarin in treatment and extended anticoagulation of acute venous
thromboembolism in the uk. thrombosis and haemostasis 2015; 114, issue 4.
dx.doi.org/10.1160/th14-12-1027.
2014
mcewan p, foos v, palmer jl, lamotte m, lloyd a, grant d. validation of the ims core diabetes
model. value health. 2014 sep;17(6):714-24. doi: 10.1016/j.jval.2014.07.007.
vellopoulou a, van agthoven m, van der kolk a, de knegt rj, berdeaux g, cure s, bianic f, lamotte
m. cost-utility of telaprevir - peginterferon - ribavirin (pr) versus
boceprevir - pr and versus pr alone in chronic hepatitis c in the netherlands.
appl health econ health policy. 2014 dec;12(6):647-59. doi: 10.1007/s40258-014-0120-y
reynolds mr, lamotte m, todd d, khaykin y, eggington s, tsintzos s, klein g. cost-effectiveness of
cryoballoon ablation for the management of paroxysmal atrial fibrillation. europace 2014
may;16(5):652-9. doi: 10.1093/europace/eut380. epub 2014 jan 2.
duran a, spaepen e, lamotte m, brosa m, gutiérrez l, restovic g. costes de los agentes
estimulantes de la eritropoyesis en el tratamiento de la anemia inducida por quimioterapia en españa:
resultados preliminares procedentes de la adaptación de un estudio belga. accepted for publication
in pharmacoeconomics spanish research articles volume 11, pages15-23 (2014).
2013
chevalier p, lamotte m, joseph a, dubois d, boeckxstaens g. in-hospital costs associated with
chronic constipation in belgium: a retrospective database study. neurogastroenterology and motility
2014 mar;26(3):368-76. doi: 10.1111/nmo.12269. epub 2013 dec 11.
max dratwa, anne-marie bogaert, koen bouman, xavier warling, remi hombrouckx, mario
schurgers, pierre dupont, anne vereerstraeten, guy van roost, karin caekelbergh, mark lamotte
and suzanne laplante. the economic burden of dialysis patients in belgium: a comparison between
haemo and peritoneal dialysis. the e-book outcomes assessment in end - stage kidney disease
measurements and applications in clinical practice. 2013 pp.208-222 (15)
chevalier p, lamotte m, van campenhout h, eyckerman r, annemans l. cost-utility of pregabalin
as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in
belgium. j med econ 2013; 16:1-10.
palmer aj; mount hood 5 modeling group, clarke p, gray a, leal j, lloyd a, grant d, palmer j,
foos v, lamotte m, hermann w, barhak j, willis m, coleman r, zhang p, mcewan p, betz brown j,
gerdtham u, huang e, briggs a, carlsson ks, valentine w. computer modeling of diabetes and its
complications: a report on the fifth mount hood challenge meeting. value health. 2013
jun;16(4):670-85. doi: 10.1016/j.jval.2013.01.002. epub 2013 apr 18.
body jj, chevalier p, gunther o, hechmati g, lamotte m. the economic burden associated with
skeletal-related events in patients with bone metastases secondary to solid tumors in belgium.
journal of medical economics 2013: 16 (5); 1-8.
2012
nevens f, colle i, michielsen p, robaeys g, moreno c, caekelbergh k, lamotte m, wyffels v.
resource use and cost of hepatitis c-related care. eur j gastroenterol hepatol. 2012
oct;24(10):1191-8. doi: 10.1097/meg.0b013e3283566658.
grabbi e, lucioni c, duran a, spaepen e, lamotte m, kutikova l, pujol b, gozzo m, iannazzo s.
analisi dei costi associati agli agenti stimolanti l’eritropoiesi nel trattamento dei pazienti con anemia
indotta da chemioterapia in italia. pharmacoeconomics 2012: 14(2): 91-100.
duran a, spaepen e, lamotte m, walter e, umuhire d, lucioni c, pinheiro b, brosa m, kutikova l,
pujol b, van bs, annemans l. cost analysis: treatment of chemotherapy-induced anemia with
erythropoiesis-stimulating agents in five european countries. j med econ. 2012;15(3):409-18. doi:
10.3111/13696998.2011.653597. epub 2012 jan 13.
2010
gerlier l, lamotte m, wille m, dubois d, meurgay f, kreuz p, vanlauwe j. the cost-utility of
autologous chondrocytes implantation using chondrocelect® in symptomatic knee cartilage lesions.
pharmacoeconomics 2010; 28: 1129-1146.
gerlier l, lamotte m, awada a, bosly a, bries g, cocquyt v, focan c, henry s,
lalami y, machiels jp, mebis j, straetmans n, verhoeven d, somers l. the use of
chemotherapy regimens carrying a moderate-to high risk of febrile neutropenia and the corresponding
management of febrile neutropenia in breast cancer and non-hodgkin’s lymphoma: a belgian expert
survey. bmc cancer 2010; 10: 642.
lamotte m, maugars y, le lay k, taïeb c. health economic evaluation of outpatient management of
fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in france. clin exp
rheumatol 2010; 28 (suppl. 63): s64-s70.
2009
caekelbergh k, nikkels a, leroy b, verhaeghe e, lamotte m, rives v. photodynamic therapy using
methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and
health economic outcomes from a real-life study. journal of drugs in dermatology 2009; 8: 992-6.
2008
herregods mc, daubresse jc, michel g, lamotte m, vissers e, vandenhoven g. discovery benelux:
comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. acta cardiologica 2008; 63:
493-9.
dendale p, hansen d, berger j, lamotte m. long-term cost-benefit ratio of cardiac rehabilitation after
percutaneous coronary intervention. acta cardiologica 2008; 63: 451-6.
annemans l, rémy v, lamure e, spaepen e, lamotte m, muchada jp, largeron n. economic
burden associated with the management of cervical cancer, cervical dysplasia and genital warts in
belgium. journal of medical economics 2008; 11: 135-150.
2007
lamotte m, annemans l. coste-efectividad de la aspirina en la prevención cardiovascular. med clin
monogr (barc). 2007;7(7):27-36
annemans l, lamotte m, clarys p, van den abeele e. health economic evaluation of controlled and
maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. eur j
cardiovasc prev rehabil. 2007 dec;14(6):815-24.
lamotte m, annemans l, bridgewater b, kendall s, siebert m. a health economic evaluation of
concomitant surgical ablation for atrial fibrillation. eur j cardiothorac surg. 2007; 32(5): 702-710.
tsutani k, igarashi a, fujikawa k, evers t, kubin m, lamotte m, annemans l. a health economic
evaluation of aspirin in the primary prevention of cardiovascular disease in japan. intern med.
2007;46(4):157-62.
2006
lamotte m, annemans l, kawalec p, zoellners y. a multi-country health-economic evaluation of
highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial
infarction. herz. 2006 dec;31 suppl 3:74-82.
annemans l, lamotte m, kubin m, evers t, verheugt fw. which patients should receive aspirin for
primary prevention of cardiovascular disease? an economic evaluation. int j clin pract. 2006
sep;60(9):1129-37.
lamotte m, piñol c, brotons c, annemans l, guardiola e, evers t, kubin m. [health economic
evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease] rev
esp cardiol. 2006 aug;59(8):807-15. spanish.
lamotte m, annemans l, kawalec p, zoellner y. a multi-country health economic evaluation of highly
concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
pharmacoeconomics. 2006;24(8):783-95.
lamotte m, annemans l, evers t, kubin m. a multi-country economic evaluation of low-dose aspirin
in the primary prevention of cardiovascular disease. pharmacoeconomics. 2006;24(2):155-69.
2005
lamotte m, annemans l, lamberts g, michielsen d, nicolas h, van cangh p, van erps p, massaer
k, dinet j, vranckx k. [the cost of complicated acute urinary retention: a patient chart analysis in
belgium] rev med liege. 2005 nov;60(11):875-81. french.
annemans l, cleemput i, lamotte m, mcneill a, hargreave t. the economic impact of using
alfuzosin 10 mg once daily in the management of acute urinary retention in the uk: a 6-month
analysis. bju int. 2005 sep;96(4):566-71.
2004
tarricone r, marchetti m, lamotte m, annemans l, de jong p. what reimbursement for coronary
revascularization with drug-eluting stents? eur j health econ. 2004 dec;5(4):309-16.
palmer aj, annemans l, roze s, lamotte m, rodby ra, de alvaro f; grupo de estudio
colaborativo idnt. [cost-efectiveness of ibersartan in type ii diabetic nephropathy with hypertension.
a spanish perspective] nefrologia. 2004;24(3):231-8. spanish.
palmer aj, annemans l, roze s, lamotte m, lapuerta p, chen r, gabriel s, carita p, rodby ra, de
zeeuw d, parving hh. cost-effectiveness of early irbesartan treatment versus control (standard
antihypertensive medications excluding ace inhibitors, other angiotensin-2 receptor antagonists, and
dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes,
hypertension, and renal disease. diabetes care. 2004 aug;27(8):1897-903.
palmer aj, annemans l, roze s, lamotte m, rodby ra, bilous rw. an economic evaluation of the
irbesartan in diabetic nephropathy trial (idnt) in a uk setting. j hum hypertens. 2004
oct;18(10):733-8.
palmer aj, annemans l, roze s, lamotte m, rodby ra, ritz e. [health economic consequences of
the use of irbesartan in patients in germany with type 2 diabetes, nephropathy and hypertension]
dtsch med wochenschr. 2004 jan 2;129(1-2):13-8. german.
2003
palmer aj, annemans l, roze s, lamotte m, rodby ra, cordonnier dj. an economic evaluation of
irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-
effectiveness of irbesartan in diabetic nephropathy trial (idnt) in the belgian and french settings.
nephrol dial transplant. 2003 oct;18(10):2059-66.
annemans l, lamotte m, levy e, lenne x: cost-effectiveness of clopidogrel versus aspirin in
patients with atherothrombosis based on the caprie trial. j med economics 2003; 6: 55-68.
annemans l, moeremans k, lamotte m, garcia conde j, van den berg h, myint h, pieters r,
uyttebroeck a. incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis
syndrome in patients with acute leukaemia and non-hodgkin's lymphoma in four european countries.
leuk lymphoma. 2003 jan;44(1):77-83.
annemans l, moeremans k, lamotte m, garcia conde j, van den berg h, myint h, pieters r,
uyttebroeck a. pan-european multicentre economic evaluation of recombinant urate oxidase
(rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in
haematological cancer patients. support care cancer. 2003 apr;11(4):249-57. epub 2003 feb 4.
lamotte m, caekelbergh k, annemans l. dépistage de la bronchopneumopathie obstructive. ibes
(institut belge de l'économie de la santé). briefing, n°40, bruxelles, janvier 2003, 6 pages
2002
caekelbergh k, lamotte m, annemans l. corticosteroïdes à inhaler chez des enfants asthmatiques.
ibes (institut belge de l'économie de la santé). briefing, n°39, bruxelles, décembre 2002, 5 pages.
caekelbergh k, lamotte m, annemans l. épidemiologie et coût de l'asthme et de la broncho-
pneumopathie chronique obstructive en belgique, ibes (institut belge de l'économie de la santé).
briefing, n°38, bruxelles, novembre 2002, 5 pages.
lamotte m, annemans l, lefever a, nechelput m, masure j. a health economic model to assess the
long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. diabetes care.
2002 feb;25(2):303-8.
2000
m. lamotte, h. debel, p. dodion: prophylaxie des pathologies thrombo-emboliques veineuses à
l'aide d'une héparine de bas poids moléculaire en chirurgie orthopédique: résultats et analyses
complémentaires d'un registre de surveillance épidémiologique. louvain med 2000; 119: 67-77..
1997
p. dendale, a. aerts, p. melis, m. lamotte: echocardiogram van de maand: acuut hartfalen bij een
jonge vrouw. tijdschr cardiol. jaargang 9, nr. 6, juni 1997: 124-5.
m. lamotte, d. schoors, p. block: misleidende st- optrekkingen. tijdschr cardiol. jaargang 9, nr. 3,
maart 1997.
1995
m. lamotte, m. kockx, m. hautekeete, j. holvoet, h. hubens: biliary phytobezoar: a medical
curiosity. american journal of gastroenterology, vol. 90. aug. 95.
posters, abstracts and workshops
2024
Martins L, Ramos M, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease
Model: Cardiovascular Outcomes in Type 2 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster
session 1 EE107 - Monday 10.30-13.00.
Lamotte M , Martins L, Ramos M. Internal Validation of the Metabo-Reno-Cardiovascular Disease
Model: Cardiovascular Outcomes in Type 1 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster
session 2 EE284 - Monday 16.00-19.00
Ramos M, Martins L, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease
Model: Mortality in Type 2 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 4 EE619 -
Tuesday 16.00-19.00
Martins L, Lamotte M, Ramos M. Internal Validation of the Metabo-Reno-Cardiovascular Disease
Model: Risk of Recurrent Cardiovascular Events in a Population With and Without Diabetes. Ispor
2024 Barcelona Nov 17-20. Poster session 5 EE779 - Wednesday 9.00-10.00
Ramos M, Martins L, Lamotte M. Internal Validation of the Metabo-Reno-Cardiovascular Disease
Model: Mortality in Type 1 Diabetes. Ispor 2024 Barcelona Nov 17-20. Poster session 5 EE780 -
Wednesday 9.00-10.00
Ramos M, Gerlier L, Uster A, Steubl D, Muttram L, Frankel AH, Lamotte M. Chronic kidney disease
progression model: development and validation. Accepted AMCP 2024 New Orleans, LA, Apr. 15-
Apr. 18, 2024. Encore presentation.
Anaya P, Chattarjee S, Al Rawashdh N, Uster A, Mazo AR, Ramos M, Gerlier L, Lamotte M. Clinical
and economic outcomes of delaying initiation of empagliflozin in chronic kidney disease (CKD)
management in the United States. Accepted AMCP 2024 New Orleans, LA, Apr. 15- Apr. 18, 2024.
ramos m, gerlier l, uster a, steubl d, muttram l, frankel ah, lamotte m. chronic kidney disease
progression model: development and validation. accepted amcp 2024 new orleans, la, apr. 15-
apr. 18, 2024. encore presentation.
2023
james altunkaya, xinyu li, talitha feenstra, mi jun keng, mark lamotte, phil mcewan, jianchao
quan, harry smolen, william valentine, michael willis jose leal, philip clarke.
estimating cross-model variability in estimates of cost-effectiveness for eleven diabetes health
economic models: a mass replication exercise. ihea conference june 10, 2023, cape town south
africa.
anaya p, chattarjee s, al rawashdh n, uster a, mazo ar, james altunkaya, xinyu li, talitha
feenstra, mi jun keng, mark lamotte, phil mcewan, jianchao quan, harry smolen, william
valentine, michael willis jose leal, philip clarke.
estimating cross-model variability in estimates of cost-effectiveness for eleven diabetes health
economic models: a mass replication exercise. ihea conference june 10, 2023, cape town south
africa.
anaya p, chattarjee s, al rawashdh n, uster a, mazo ar, ramos m, gerlier l, lamotte m. cost-
effectiveness analysis of empagliflozin versus standard of care (soc) in patients with chronic
kidney disease (ckd) in the us. poster presentation at amcp nexus 2023 orlando, fl, oct. 16-
oct. 19, 2023.
martins l, panchal m, ramos m, lamotte m. time in range as alternative to hba1c change in the
iqvia core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee625
mørup mf, taieb v, willems d, rose m, lamotte m, gerlier l, thom h. the cost-effectiveness of a
bimekizumab versus secukinumab treatment pathway in patients with active axial spondyloarthritis
in scotland. value in health, volume 26, issue 11, s2 (december 2023). ee192
borges m, soares m, lamotte m, olivieri av, shukla s, freitas p, silva miguel l. assessing the cost-
effectiveness of semaglutide 2.4 mg injection for chronic weight management in portugal. value in
health, volume 26, issue 11, s2 (december 2023). ee277
uster a, ramos m, gerlier l, muttram l, steubl d, frankel ah, lamotte m. chronic kidney disease
progression model (ckd-pm): development and validation. american society of nephrology (asn).
abstract 3943697. november 3, 2023 from 10:00 am to 12:00 pm. poster board #: fr-po940
ramos m, gerlier l, uster a, aguirre ar, muttram l, frankel ah, lamotte m. cost-effectiveness of
empagliflozin in chronic kidney disease (ckd) management in the uk. ispor eu copenhagen
november 2023. value in health, volume 26, issue 11, s2 (december 2023) ee420.
martins l, panchal m, ramos m, lamotte m. update to the macrovascular submodels of the iqvia
core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee319
martins l, panchal m, ramos m, lamotte m. comparing three indirect cost approaches in the
iqvia core diabetes model. value in health, volume 26, issue 11, s2 (december 2023). ee470
mørup mf, taieb v, willems d, rose m, lamotte m, gerlier l, thom h. the cost-effectiveness of a
bimekizumab versus secukinumab treatment pathway in patients with active axial spondyloarthritis
in scotland. value in health, volume 26, issue 11, s2 (december 2023). ee192
borges m, soares m, lamotte m, olivieri av, shukla s, freitas p, silva miguel l. assessing the cost-
effectiveness of semaglutide 2.4 mg injection for chronic weight management in portugal. value in
health, volume 26, issue 11, s2 (december 2023). ee277
2022
mallory farrar, milena anatchkova, richard auchus, carine courtillot, katelyn cutts, adrian dobs,
diala el-maouche, henrik falhammar, andre lacroix, natalie taylor, philippe touraine, mark
lamotte, conor o'donoghue, chuck yonan. treatment patterns and unmet needs in adults with
classic congenital adrenal hyperplasia: a modified delphi consensus study. accepted as a poster at
amcp (2022 march 30-april 1) and abstract published in journal of managed care & specialty
pharmacy (jmcp).
mark lamotte, john dipersio, david siegel, haddas meron, philip serlin, laetitia gerlier. cost-
effectiveness analysis of motixafortide on top of g-csf for stem-cell
mobilization for autologous bone marrow transplantation in patients with
multiple myeloma. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual
(ee56).
martins l, ramos m, lamotte m. contrasting three hba1c progression equations using the iqvia
core diabetes model. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual
(ee366).
martins l, ramos m, lamotte m. contrasting four type 2 diabetes cardiovascular risk equations for
east asia using the iqvia core diabetes model. ispor 2022 may 15-18, 2022 washington, dc,
usa area and virtual (ee262).
olivieri av, larsen s, luckevich m, chan k, lamotte m. the cost-effectiveness of subcutaneous
semaglutide 2.4mg injection in the management of obesity in canada using the core obesity
model. ispor 2022 may 15-18, 2022 washington, dc, usa area and virtual (ee464)
kobina quansah, kåre hansen, katalina chan, sergey muratov, shoghag khoudigian, mark
lamotte. smart insulin pen caps versus standard of care: a canadian cost-effectiveness analysis.
accepted as a short oral discussion with presentation number: 666 at the 58th easd annual
meeting, 19 - 23 september 2022.
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1
diabetes using the iqvia core diabetes model. ispor 2022 november 9, 2022 vienna, austria
area and virtual (ee649).
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1
diabetes using the iqvia core diabetes model. mount hood diabetes challenge malmo 2022,
september 24.
martins l, ramos m, lamotte m. contrasting 4 different mortality predictions in patients with type 1
diabetes using the iqvia core diabetes model. ispor eu vienna 6-9 november 2022. ee649
m lamotte, j dipersio, ds siegel, h meron, and l gerlier. cost-effectiveness analysis of
motixafortide versus plerixafor in stem cell mobilization for autologous transplantation in patients
with multiple myeloma. oral poster at the american society of hematology dec 11 2022. new
orleans. publication number: 4848
2021
lopes s, grand t, johansen p, lamotte m, olivieri av. exploring different ways to predict mortality in
a cost-effectiveness model for obesity. accepted as a poster at the international diabetes federation
(idf) congress 2021. 06-11 december.
2020
ramos m, monteiro s, olivieri av, lamotte m. contrasting three type 2 diabetes
cardiovascular risk equations for east asia with ukpds82 using the iqvia
core diabetes model. ispor us 2020 orlando. value in health, volume 23, issue 5, s1 (may
2020) code pdb56
ramos m, monteiro s, lamotte m. impact of using different types of hba1c
progression in the iqvia core diabetes model. ispor us 2020 orlando value in health,
volume 23, issue 5, s1 (may 2020) code pdb52.
monteiro s, ramos m, lamotte m. does including acute pancreatitis as a
complication have an impact on cost-effectiveness analyses using the iqvia
core diabetes model? ispor us 2020 orlando. value in health, volume 23, issue 5, s1 (may
2020) code pdb44.
kiri s, arteaga duarte ca, lee e, low r, tsakeu e, lamotte m, gerlier l. cost-effectiveness
analysis of certolizumab pegol versus secukinumab and ixekizumab in non-radiographic axial
spondyloarthritis in the u.s. amcp nexus 2020 virtual october 19.
kiri s, arteaga duarte c, lamotte m, gerlier l. budget impact analysis of a reduced maintenance
dose of certolizumab pegol in patients with axial spondyloarthritis in the united kingdom. ispor
europe 2020 virtual conference milano nov 16-19 abstract id# 107821.
cai r, eichner m, schwehm m, rajaram s, mould-quevedo j, lamotte m. cost-effectiveness of the
cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in
germany. results of a dynamic transmission modelling approach. ispor europe 2020 virtual
conference milano nov 16-19 abstract id# 105463.
ehlers l, lamotte m, monteiro s, sandgaard s, holmgaard p, frary ec, staehr p, ejskjaer n. the
cost-effectiveness of empagliflozin in type 2 diabetes in denmark, incorporating cardiovascular
outcomes. ispor europe 2020 virtual conference milano nov 16-19 abstract id# 107114.
ramos m, monteiro s, lamotte m. does including egfr along to hba1c as a driver of treatment
switch changes outcomes in cost-effectiveness analyses in type 2 diabetes? ispor europe 2020
virtual conference milano nov 16-19 abstract id# 108179.
mitsuo r, demiya s, tawseef a, de moor r, ramos m, lamotte m. the asian type 2 diabetes
cardiovascular risk equations simulation using the iqvia core diabetes model. digital poster at the
63rd annual meeting of the japan diabetes society 2020.
2019
ramos m, foos v, ferrufino c, yu-isenberg k, lamotte m. the relationship between poor
adherence and hba1c and weight changes in patients with type 2 diabetes.
pdb116, november 2018, ispor europe 2018, barcelona, spain.
lamotte m, salem a, mettam s, ustyugova a, zhang yj, ramos m. projected long-term clinical
benefit and cost-effectiveness of empagliflozin compared to glimepiride in patients with type 2
diabetes in china. ada scientific sessions 2019. san francisco 7-11 june. 1292-p.
monteiro s, ramos m, altrabsheh e, gurjar k, olivieri a, lamotte m. contrasting framingham risk
equations in type 2 diabetes using the iqvia core diabetes model. ispor 24 th annual international
meeting new orleans us, may 18-22 2019. pdb35
olivieri a, ramos m, monteiro s, altrabsheh e, gurjar k, lamotte m. contrasting three type
2 diabetes cardiovascular risk equations for east asia with ukpds82 using
the iqvia core diabetes model. ispor 24 th annual international meeting new orleans us,
may 18-22 2019. pdb26
ramos m, olivieri a, monteiro s, altrabsheh e, gurjar k, lamotte m. body mass index
associated utility approaches in the iqvia core diabetes model. ispor 24 th
annual international meeting new orleans us, may 18-22 2019. pdb23
gurjar k, ramos m, monteiro s, altrabsheh e, olivieri a, lamotte m. comparability of results using
two alternative versions of the iqvia core diabetes model. submitted to ispor 24 th annual
international meeting new orleans us, may 18-22 2019. pdb30
altrabsheh e, monteiro s, ramos m, gurjar k, olivieri a, lamotte m. association between
cardiovascular disease risk factors and hypoglycaemic events in type 2 diabetes using the iqvia
core diabetes model. ispor 24 th annual international meeting new orleans us, may 18-22 2019.
pdb64.
monteiro s, ramos m, lamotte m. health economic effects of the updated foot
ulcer submodel in the iqvia core diabetes model. ispor europe 2019 copenhagen.
tuesday nov 5 2019. pdb17.
ramos m, monteiro s, altrabsheh e, lamotte m the clinical and economic impact of
adding an adherence module to the iqvia core diabetes model. ispor europe
2019 copenhagen. tuesday nov 5 2019. pdb61.
farag a, abdel moety h, hassan l, pathak p, lamotte m, levorsen a. the cost-
effectiveness of enoxaparin in the prevention of venous thromboembolism in
patients undergoing major surgery in egypt. ispor europe 2019 copenhagen.
monday nov 4 2019. psu18.
sekongo ym, asamoah-akuoko l, lamotte m, bah a, dierick k. health economic value of
blood in ivory coast: the case of maternal bleeding. ispor europe 2019
copenhagen. wednesday nov 6 2019. pmd16.
owusu-ofori spo, asamoah-akuoko l, lamotte m, bah a, dierick k. health economic value
of blood in ghana: the case of maternal bleeding. ispor europe 2019 copenhagen.
monday nov 4 2019. pns62.
dierick k, lamotte m, owusu-ofori spo, sekongo ym, rajab ja, asamoah-akuoko l, magutu v,
bah a health economic value of blood in sub-saharan africa: the case of
maternal bleeding. ispor europe 2019 copenhagen. monday nov 4 2019. pns158.
magutu v, rajab ja, asamoah-akuoko l, lamotte m, bah a, dierick k. the value of blood in
sub-saharan africa. ispor europe 2019 copenhagen. monday nov 4 2019. pns184.
cogle s., ramos m., taylor k., roberts p., martindale r. cost benefit analysis of parenteral nutrition
delivered via three chamber bags versus hospital-compounded bags. asph summer meetings 2019
exhibitions (46-t)
l. martins, p. amaro, m. l. carvalho, j. p. santos. x-ray fluorescence analysis using a standardless
method. exsa quantitative methods in x-ray spectrometry, almada, portugal, lisbon, 12-17 of may
2019, almada, portugal
2018
foos v, mcewan p, lamotte m. review and validation of cardiovascular risk prediction models in
east asian populations. value health 2018; 21: s220
mafalda ramos, mark lamotte, laetitia gerlier, per svangren, anna miquel cases, john haughney.
the cost-effectiveness of physical activity in the management of copd patients in the uk. ers 2018
international congress. paris. sunday sept 16 pa701.
salem a, ramos m, hu h, zhong h, lamotte m. the health economic impact of optimizing post-
hospitalization management for an exacerbation in copd patients in china. ispor asia pacific 2018
8-11 september 2018. prs13.
salem a, hu h, ramos m, zhong h, lamotte m. the economic impact of optimized post-
hospitalization management for an exacerbation in copd patients in china. prs31, november
2018, ispor europe 2018, barcelona, spain.
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. patient and
caregiver productivity loss and indirect costs associated with cardiovascular events in europe.
european heart journal, volume 39, issue suppl_1, 1 august 2018, ehy565.p2561
ramos m, volker f, ustyugova a, hau n, gandhi p, lamotte m. cost-effectiveness analysis of
empagliflozin in comparison to standard of care, sitagliptin and saxagliptin based on cardiovascular
outcome trials. easd 2018. berlin october 2. poster 863.
ramos mafalda, volker foos, kristina yu-isenberg, mark lamotte. the relationship between poor
adherence and hba1c and weight changes in patients with type 2 diabetes. mount hood diabetes
challenge 2018. oct 6 abstract session 5.
mark lamotte, volker foos, anastasia ustyugova, nikco hau, pranav gandhi, mafalda ramos cost-
effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on
cardiovascular outcome trials. mount hood diabetes challenge 2018. oct 6 abstract session 5.
de francesco m, lopes s, meincke hh, vega g, lean m, lamotte m. core obesity model to
assess the cost-effectiveness of weight management interventions. ispor
europe 2018 barcelona, spain. november, 2018. psy104.
ramos m, foos v, ustyugova av, hau n, gandhi p, lamotte m. cost-effectiveness
analysis of empagliflozin in comparison to sitagliptin and saxagliptin based
on cardiovascular outcome trials. ispor europe 2018 barcelona, spain. november,
2018. (ce1-podium presentation)
lamotte m, ramos m, salem a, ustyugova av, hau n, gandhi p, foos v. cost-effectiveness
analysis of empagliflozin in comparison to liraglutide based on
cardiovascular outcome trials. pdb76.
dudek dz, lamotte m, sawicka m, huczek zj, depukat r, rajtar-salwa r, krupiarz m, duma k,
sidelnikov e. the 1-year productivity loss and indirect costs after acute
cardiovascular events in poland. pcv62, november 2018, ispor europe 2018,
barcelona, spain.
salem a, ramos m, hu h, zhong h, lamotte m. the economic impact of optimized post-
hospitalization management for an exacerbation in copd patients in china.
prs31, november 2018, ispor europe 2018, barcelona, spain.
l martins, s pessanha, p amaro, m l carvalho, j p santos. monte carlo simulation of an edxrf
setup with triaxial geometry: using rayleigh to compton ratio to evaluate the mean atomic number of
unknown samples. european conference on x-ray spectrometry. 24–29 june 2018, ljubljana,
slovenia
s pessanha, s silva, l martins,m l carvalho. taking advantage of compton-to-rayleigh ratio in
edxrf spectra to recognize hydroxyapatite-based materials. european conference on x-ray
spectrometry. 24-29 june 2018, ljubljana, slovenia
â. andrade, o. bezerra, i. queralt, s. diez, v. neves, w. souza, s. pessanha, l. martins, m. l.
carvalho, j. d. fabris, d. guimarães. quantitative assessment of mercury and other heavy metals on
freshwater fish and vegetation collected in areas of gold mining in brasil. european conference on x-
ray spectrometry. 24-29 june 2018, ljubljana, slovenia
l. martins, p. amaro, m. l. carvalho, j. p. santos. método de análise por fluorescência de raios-x
sem recurso a padrões. física 2018, 21ª conferência nacional de física, 28º encontro ibérico para o
ensino da física, 2018, covilhã, portugal.
2017
foos v, lamotte m, mcewan p, jiang x, zhang yl, qu s, de moor r, ramos m, xiong t, wang k.
assessing the economic burden of type 2 diabetes in china reflecting the
current standard of the disease management and for improved management
scenarios using a modeling approach. ispor 22nd annual international meeting boston,
ma, usa may, 2017 pdb40.
mcewan p, foos v, lamotte m. approaches to standardising cardiovascular risk
equation endpoints in order to facilitate their inclusion within a type 2
diabetes model. ispor 22nd annual international meeting boston, ma, usa may, 2017 prm69
foos v, lamotte m, altrabsheh e, sathananthan a, mcewan p. determinants of the
relationship between improved glucose control and modeled health
outcomes in type 2 diabetes simulation models. ispor 20th annual european
congress glasgow, scotland november, 2017 prm91
foos v, lamotte m, sathananthan a, altrabsheh e, mcewan p. exploration of run-time
requirements in probabilistic sensitivity analysis utilizing a patient level
based type 2 diabetes simulation model. ispor 20th annual european congress
glasgow, scotland november, 2017 prm101
gerlier l, sidelnikov e, kutikova l, lamotte m, amarenco p, kotseva k, annemans l. interim
results of a multi-country survey to evaluate productivity loss and indirect
costs after cardiovascular events in europe. ispor 20th annual european congress
glasgow, scotland november, 2017. cv1
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. work
productivity losses in the year following acute coronary syndrome or stroke: interim results of a multi-
country survey in europe. american heart association (aha) scientific sessions 2017, anaheim,
california, usa (m2005).
kotseva k, gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l, amarenco p. work
productivity losses in the year following acute coronary syndrome or stroke: interim results of a multi-
country survey in europe. american heart association (aha) scientific sessions 2017, anaheim,
california, usa (m2005).
foos v, mcewan p, lamotte m. comparison of cost-effectiveness acceptability
curves (ceac) in modeled analyses with and without established
heterogeneity of patient characteristics. ispor 22nd annual international meeting
boston, ma, usa may, 2017 prm72.
willis m, feenstra t, lamotte m, brennan a. comparing, contrasting, and validating health
economic decision models: experiences from the latest mt. hood challenge in diabetes and
lessons for other disease areas. ispor 20th annual european congress glasgow, scotland
november, 2017. workshop 17.
l martins, s pessanha, p amaro, m l carvalho, j p santos. monte carlo simulation of an edxrf
setup with triaxial geometry: using rayleigh to compton ratio to evaluate the mean atomic number of
unknown samples, 11th joint iberian meeting on atomic and molecular physics (iber) 2017,
barcelona, spain
l. martins. x-ray fluorescence analysis using a standardless method. 2nd doctoral congress in
engineering, dce 2017, oporto, portugal
2016
mcewan p, gordon j, foos v, lamotte m, evans m, paldánius pm. estimating the cost-effectiveness
of vildagliptin versus sulfonylurea in combination with metformin: clinical guidelines versus clinical
practice. ispor 21 st annual international meeting – washington 2016. presentation code: pdb31.
mcewan p, gordon j, foos v, lamotte m, evans m, paldánius pm. cost-effectiveness of type 2
diabetes treatments in middle eastern countries: an economic evaluation of the edge study using
patient level data. ispor 21st annual international meeting, washington, dc, may 21-25 2016.
pdb32.
foos v, lamotte m, mcewan p. the comparison of cardiovascular incidence predictions in type 1
diabetes utilizing alternative risk prediction models. ispor 21st annual international meeting,
washington, dc, may 21-25 2016. prm85
foos v, lamotte m, mcewan p. appropriate allocation of time horizons for lifetime modeling
projections in type 2 diabetes may improve the precision of cost effectiveness evaluations. ispor
21st annual international meeting, washington, dc, may 21-25 2016. prm91.
foos v, lamotte m, mcewan p. comparing direct and indirect cost of type 2 diabetes individuals
across three age ranges in the us. ispor 21st annual international meeting, washington, dc, may
21-25 2016. prm92
mcewan p, foos v, lamotte m, evans m. quantifying the health economic benefit of key therapeutic
outcomes in the management of type 2 diabetes and assessing their inter-relationship. ispor 21st
annual international meeting, washington, dc, may 21-25 2016. prm95.
de francesco m, johnson p, lamotte m. cost-effectiveness of allogenic pancreatic islet
transplantation versus whole pancreas transplantation in england and wales. ispor 21st annual
international meeting, washington, dc, may 21-25 2016. pdb42.
todoran tm, goldfarb s, peña cs, ferrufino cp, stacey kowal s, de francesco m, lamotte m, king
a. budget impact of contrast media choice and contrast induced acute kidney in high-risk patients
undergoing invasive coronary angiography with or without percutaneous coronary intervention from a
us hospital perspective. ispor 21st annual international meeting, washington, dc, may 21-25
2016. pmd14.
foos v, lamotte m, mcewan p. appropriate time horizons for modelling in type 2 diabetes may
improve the precision of economic evaluation. ada scientific sessions 2016. publication number
356-or. monday jun 13, 2016 4:30 pm - 6:30 pm. oral presentation.
foos v, lamotte m, mcewan p. comparing direct and indirect costs of type 2 diabetes across
three age ranges in the u.s. ada scientific sessions 2016. publication number 112-or. saturday
jun 11, 2016 1:45 pm - 3:45 pm. oral presentation.
de francesco m, lamotte m, johnson p. cost-effectiveness of pancreatic islet transplantation vs.
whole pancreas transplantation in the uk. ada scientific sessions 2016. publication number 180-
or. saturday jun 11, 2016 4:00 pm - 6:00 pm. oral presentation.
mcewan p, foos v, lamotte m, evans m. characterising the health economic benefit of key
therapeutic outcomes in the management of type 2 diabetes. ada scientific sessions 2016. poster:
1251-p.
mcewan p, foos v, lamotte m. replacing input probability distributions with mean values can bias
simulation output: an illustration using the core diabetes model. ispor 19th annual european
congress, vienna, austria, 29th october - 2nd november 2016. prm 85.
foos v, mcewan p, lamotte m. implications of introducing patient heterogeneity in cost effectiveness
modeling. ispor 19th annual european congress, vienna, austria, 29th october - 2nd november
2016. prm 81.
chevalier p, van gils c, lamotte m. description of first-line treatments in patients with non-resectable
colorectal cancers in belgium. ispor 19th annual european congress, vienna, austria, 29th october
- 2nd november 2016. pcn 233.
chevalier p, van gils c, lamotte m. in-hospital mortality and complications following surgical
resection of glioblastoma. ispor 19th annual european congress, vienna, austria, 29th october -
2nd november 2016. pcn 45.
ramos m, lamotte m, chevalier p, goodall g. assessing the cost-effectiveness of transcatheter
aortic valve implantation in inoperable patients with severe aortic stenosis in uk. ispor 19th annual
european congress, vienna, austria, 29th october - 2nd november 2016. pmd 70.
chevalier p, lamotte m. hospital resources and co-morbidities associated with crohn's disease and
ulcerative colitis in belgium. ispor 19th annual european congress, vienna, austria, 29th october -
2nd november 2016. pgi 13.
chevalier p, tsakeu e, lamotte m. epidemiology of patients receiving hematopoietic stem cell
patients in belgium. ispor 19th annual european congress, vienna, austria, 29th october - 2nd
november 2016. psy 159.
caekelbergh k, chevalier p, lamotte m, kutikova l, schutyser e, annemans l. short and long term
costs associated with different cardiovascular events in belgium. ispor 19th annual european
congress, vienna, austria, 29th october - 2nd november 2016. php 108.
gerlier l, sidelnikov e, kutikova l, lamotte m, annemans l. rationale and design of a multi-center
survey to evaluate productivity losses and indirect costs after cardiovascular events in europe. ispor
19th annual european congress, vienna, austria, 29th october - 2nd november 2016. prm 216.
2015
portilla c, gonzalez a. f, cortés j m, castro a., sterling sp., ramos m. the cost-effectiveness of pd-
apcc versus rfviia in pediatric patients with haemophilia type a and inhibitors with mild to moderate
joint bleeding in colombia. isth 2015 congress. june 20-25. (abs-1196)
ramos m, nivelle e, lamotte m, ehm a: assessing the cost-effectiveness of using
3chamber bags compared to hospital compounded bags and separate bottle
systems for hospitalized patients requiring parenteral nutrition. 11th world
congress: "de gustibus disputandum non est!" health economics and nutrition: an ihea world
congress. milan june 2015.
soto j, gonzález l, bravo a, bergés a, pompa, rodriguéz m, silva s, paredes r, lamotte m. the
cost-effectiveness of pd-apcc versus rfviia in pediatric patients with
haemophilia a and inhibitors with mild to moderate joint bleeding in mexico.
isth15abs-3646. po355-wed. isth conference toronto june 24 2015.
lovato e, warburton m, mcewan p, lamotte m, foos v. the importance of appropriately
incorporating the effects of hypoglycaemia within a health economic model when hypoglycaemia rates
are high. easd conference stockholm 2015 abstract # 52.
m. lamotte, v. foos, p. mcewan. contrasting eight cardiovascular risk equations for use in type 2
diabetes cohorts using the core diabetes model. stockholm 2015 abstract #1159
ramos m, caekelbergh k, lamotte m. the economic burden of poor adherence to statins in
belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano
congressi in milan, italy. pcv169
chevalier p, lamotte m. an epidemiological evaluation of the incidence of deep venous thrombosis
and pulmonary embolism in patients with hip or knee replacement surgery and of its impact on the
average length of stay and hospitalization cost. ispor 18th annual european congress held 7-11
november 2015 at the mico-milano congressi in milan, italy. pcv85.
chevalier p, lamotte m. an epidemiological evaluation of the impact of percutaneous coronary
interventions on the hospitalization cost, length of stay and mortality of patients hospitalized with
acute coronary syndromes. ispor 18th annual european congress held 7-11 november 2015 at the
mico-milano congressi in milan, italy. pcv91.
ramos m, brouyère s, caekelbergh k, lamotte m. the economic consequences of the use of
antidepressants in belgium: prescribing behavior and misuse of antidepressants. ispor 18th annual
european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. pmh48.
caekelbergh k, ramos m, lamotte m. the economic consequences of the use of antidepressants in
belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano
congressi in milan, italy. pmh49.
lamote m. caekelberg k. ramos m. ims health report. appropriate use of medicines in the belgian
health-care context (2015)
ramos m, haughney j, henry n, lindner l, lamotte m. assessing the cost-effectiveness
of using aclidinium bromide 400 μg /formoterol fumarate dihydrate 12 μg
compared to aclidinium bromide 400 μg in the management of moderate to
severe chronic obstructive pulmonary disease. ispor 18th annual european
congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. ce4.
caekelbergh k, ramos m, lamotte m. the economic consequences of the use of antibiotics in
belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano
congressi in milan, italy. php132.
ramos m, caekelbergh k, lamotte m. avoidable hospitalizations due to medication errors in
belgium. ispor 18th annual european congress held 7-11 november 2015 at the mico-milano
congressi in milan, italy. php136.
gerlier l, lamotte m, dos santos s, schwehm m, eichner m. public health outcomes of
paediatric influenza vaccination with an intranasal tetravalent live
attenuated vaccine in belgium using a dynamic transmission model ispor 18th
annual european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy.
pin9.
chevalier p, lamotte m. hospitalization cost and length of stay associated with ophthalmological
surgery depending on the diabetic status. ispor 18th annual european congress held 7-11
november 2015 at the mico-milano congressi in milan, italy. pdb40.
gerlier l, lamotte m, chevalier p. assessing the burden of systemic lupus
erythematosus in belgium using a longitudinal hospital records database.
ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in
milan, italy. psy51.
foos v, lamotte m, mcewan p. contrasting predictions of cardiovascular
incidence derived from alternative risk prediction models in type 1 diabetes.
ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in
milan, italy. prm72.
foos v, lamotte m, mcewan p. contrasting model predicted life expectancy in
patients with type 2 diabetes across different mortality risk prediction
models versus data from the canadian chronic disease surveillance system.
ispor 18th annual european congress held 7-11 november 2015 at the mico-milano congressi in
milan, italy. prm74.
mcewan p, foos v, lamotte m. the importance of accounting for baseline
hypoglycaemia frequency when modelling hypoglycaemia disutility in type 1
diabetes mellitus. ispor 18th annual european congress held 7-11 november 2015 at the
mico-milano congressi in milan, italy. prm84.
mcewan p, foos v, lamotte m.validating approaches to modelling end-stage renal
disease using the ims core diabetes model. ispor 18th annual european congress held
7-11 november 2015 at the mico-milano congressi in milan, italy. prm85.
mcewan p, foos v, lamotte m. the impact of baseline hba1c and hba1c trajectories
on time to therapy escalation in type 2 diabetes mellitus. ispor 18th annual
european congress held 7-11 november 2015 at the mico-milano congressi in milan, italy. prm88.
mcewan p, foos v, lamotte m. investigating the impact of contemporary risk
factors for diabetes complications and their evolution on risk prediction
using the ukpds 82 equation. ispor 18th annual european congress held 7-11 november
2015 at the mico-milano congressi in milan, italy. prm98.
p mcewan, m evans, m lamotte, v foos. assessing the relative contribution to
changes in quality-adjusted life expectancy associated with hba1c, weight
and hypoglycaemia across multiple risk equations with the core diabetes
model (cdm) ispor 20th annual international meeting - philadelphia 2015. presentation code:
prm74
p mcewan, m lamotte, v foos. impact of single risk factor changes on long-term
outcomes and cost in a type 2 diabetes modeling study contrasting
projections with ukpds68, swedish national diabetes registry and the
advance risk equations. ispor 20th annual international meeting - philadelphia 2015.
presentation code: prm37
v foos, m lamotte, p mcewan. contrasting the relative risk reduction of
cardiovascular events in the core diabetes model associated with single
risk factor changes across alternative risk engines: ukpds68, ukpds82 and
swedish national diabetes registry equations ispor 20th annual international
meeting - philadelphia 2015. presentation code: prm73
volker foos, mark lamotte, phil mcewan. contrasting cost-effectiveness results
derived from contemporary sets of alternative risk equations in type 2
diabetes ispor 20th annual international meeting - philadelphia 2015. presentation code: prm23
jugrin av, ustyugova av, lamotte m, sunderland tj. the costeffectiveness of
dabigatran etexilate compared with edoxaban in the treatment of acute
venous thromboembolism in the uk. ispor 20th annual international meeting -
philadelphia 2015. presentation code: pcv78
c. santos, m. guerra, m. fonseca, v. corregidor, l. c. alves, h. silva, a. costa, l. martins, h. luis,
m. l. carvalho. measurement of the ca/p ratio of healthy bone samples by micro-pixe, pige, and
micro-xrf. 22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
m. streicher, v. corregidor, n. catarino, l.c. alves, n. franco, m. fonseca, l. martins, e. alves,
e.m. costa, b.a. dedavid. study of in distribution on gainsb: al crystals by ion beam techniques .
22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
a. f. silva, m. guerra, c. santos, m. c. carvalho, a. costa, l. martins, m. l. carvalho, j. p. santos,
m. capelão, m. fonseca. a study of trace elements in canine elbow dysplasia by pige and xrf.
22nd international conference on ion beam analysis. 2015, june 14-19, opatija, croatia
m. fonseca, l. martins, a. p. jesus. erya profiling: a code for depth profiling of light elements in
inhomogenous sample by pige. 22nd international conference on ion beam analysis. 2015, june
14-19, opatija, croatia
2014
lamotte m, gerlier l, caekelbergh k, lalji k, polifka j, lee e. impact of a pharmacological
cardioversion with vernakalant on the management cost of recent atrial
fibrillation in belgium. ispor amsterdam 2014. pcv103.
gerlier l, weil-olivier c, carrat f, lenne x, lamotte m, greneche s, eichner m. public health
and economic impact of vaccinating children with a quadrivalent live
attenuated influenza vaccine in france using a dynamic transmission model.
ispor amsterdam 2014. pin61
chevalier p, de beule j, lamotte m, hunsche e, régulier e. cost of a pulmonary arterial
hypertension-related hospitalization in belgium. ispor amsterdam 2014.
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. the cost-effectiveness of
dabigatran etexilate compared with warfarin in the treatment and
secondary prevention of acute venous thromboembolism in the uk. ispor
amsterdam 2014. pcv98
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. cost-effectiveness of
dabigatran etexilate compared with rivaroxaban in the treatment of acute
venous thromboembolism in the uk. ispor amsterdam 2014. pcv95
jugrin a, ustyugova a, urbich m, lamotte m, sunderland t. the cost-effectiveness of
dabigatran etexilate compared with warfarin and rivaroxaban in the
treatment of acute pulmonary embolism in the uk. ispor amsterdam 2014. pcv96
lamotte m, wyffels v, knudsen ms, troelsgaard a, hemels m. health economic evaluation of
canagliflozin in the treatment of type 2 diabetes mellitus in belgium [internet]. vol. 17, value in health.
2014. p. a248. a
foos v, mcewan p, lamotte m, grant d. all-cause mortality validation of the core
diabetes model against predictions of the charlson comorbidity index. ispor
amsterdam 2014. prm87.
mcewan p, grant d, lamotte m, foos v. quantifying nonlinear effects in stochastic
markov simulation using ukpds 68 and ukpds 82 equations in type 2 diabetes
modeling analysis with the ims core diabetes model (cdm). ispor amsterdam 2014.
prm17.
2013
ramos m, vellopoulou k, lamotte m, chang cj, carr e. a health economic evaluation of fenofibric
acid in combination with statins in the prevention of cardiovascular disease in taiwanese mixed
hyperlipidemia patients. value in health. 2013. vol. 16, issue 7, page a526. ispor 16 th annual
european congress
beaudet a., grabbi e., maurel f., >m. ramos, lebioda a. review of cost of diabetes complications in
four european countries. ispor 16 th annual european congress, dublin (pdb71)
gil f. r, ramos m. análisis de costes de los tratamientos para la maduración cervical e
inducción al parto. x reunión de la sociedad de obstetricia y ginecología de la comunidad
valenciana. 2013.
matthew reynolds, mark lamotte, derick todd, yaariv khaykin, simon eggington, stelios tsintzos,
gunnar klein. cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial
fibrillation. boston atrial fibrillation symposium jan 2013. poster 29. abstract in journal of
cardiovascular electrophysiology.
lamotte m, chevalier p, vandebrouck t. the burden of hospitalizations due to insulin
related hypoglycemia in belgium. ispor 18th annual international meeting - new orleans
2013. pdb33
mcewan p, foos v, grant d, lamotte m, palmer jl, lloyd a.drivers of cost-effectiveness
in type-2 diabetes mellitus. ispor 18th annual international meeting – new orleans 2013.
pdb53
mcewan p, lamotte m, grant d, palmer jl, lloyd a, foos v. assessing the consistency of
absolute cardiovascular risk prediction and relative risk reduction in type-
2 diabetes mellitus. ispor 18th annual international meeting – new orleans 2013. pdb54
mcewan p, foos v, grant d, palmer jl, lamotte m, lloyd a. do existing risk equations fail
to adequately account for the relationship between body mass index and
mortality in subjects with type-2 diabetes? ispor 18th annual international meeting –
new orleans 2013. pdb55
foos v, mcewan p, grant d, palmer jl, lamotte m, lloyd a. the cost and productivity
consequences of non-severe hypoglycaemic episodes (nshe) in patients
treated with sulfonylurea or dpp4 dual combination oral therapy. ispor 18th
annual international meeting - new orleans 2013. pdb57
chevalier p, lamotte m, rigney u, engstrom g, emmas c. impact of initiating statin
therapy at a high dose - a retrospective observational study populations in
the united kingdom. ispor 18th annual international meeting – new orleans 2013. pcv14
jugrin av, lamotte m, malfait m, vandebrouck t. the cost-utility of insulin degludec
compared with current standard of care in the management of type one and
type two diabetes mellitus in belgium. ispor dublin 2013 number 45328.
jugrin av, caekelbergh k, vanacker j, vancauwenberghe l, lamotte m. the cost-utility of
catheter-based renal denervation as compared to current standard of care
for resistant hypertension in belgium. ispor dublin 2013 number 46042.
caekelbergh k, gerlier l, lamotte m, kinoo d, meurgey f, berdeaux g. the current
management and costs of irritable bowel syndrome with constipation in
belgium: a 2-round expert survey. ispor dublin 2013 number 44901.
gerlier l, caekelbergh k, lamotte m, kinoo d, meurgey f, berdeaux g cost-utility analysis
of linaclotide in the treatment of irritable bowel syndrome with
constipation in belgium. ispor dublin 2013 number 44843.
vandekerckhove s, lamotte m, petit c. cost-minimization analysis of ferumoxytol in
the management of anemia in patients with chronic kidney disease in belgium.
ispor dublin 2013 number 46180.
lamotte m, vellopoulou k, richir k, smets j, grabe k, coppens k. the cost-utility of fidaxomicin as
compared to current standard treatment in the management of clostridium difficile infections in
belgium. ispor dublin 2013 number 44107.
2012
a duran, e spaepen, m lamotte, d eheberg, a jugrin, l kutikova, b pujol, e kunz, l annemans.
cost of erythropoiesis-stimulating agents (esas) in the treatment of chemotherapy-induced
anaemia in germany. 17th congress of the european association of hospital pharmacists, 21-23
march 2012, vienna.
nivelle e, mathou f, lamotte m. assessing the budget impact of using scanbag® in ct in 6
european countries. ispor us conference june 3-8 2012, washington dc. pmd13
gerlier l, midy f, lièvre m, maurel f, cohn e, vellopoulou k, lamotte m. assessing the cost-
effectiveness of the recommended antihypertensive drug classes in france using a lifetime markov
model. ispor us conference june 3-8 2012, washington dc. cvd46.
gerlier l, midy f, lièvre m, maurel f, cohn e, vellopoulou k, lamotte m. a lifetime cost-effectiveness
analysis of the recommended antihypertensive drug classes in france. 9th htai annual meeting. hta
in integrated care for a patient centered system, bilbao from 23 to 27 june 2012. poster 363
lamotte m, chevalier p, foos v, mcewan p, lloyd a, palmer j, grant d. the cost of diabetes
complications in belgium. the mount hood six challenge. baltimore, usa june 7 and 8 2012.
conference session 2. june 7 1.30, first presentation.
holtzer-goor k, van de kerckhove s, van den steen d, van megen y, huijgens p, lamotte m, uyl-de
groot c. modelling the 10-year cost-effectiveness of bendamustine as first line treatment for chronic
lymphocytic leukaemia in the netherlands. 17 th eha conference amsterdam 14-17 june 2012.
poster 1089.
palmer jl, caputo j, foos v, grant d, lamotte m, lloyd a, mcewan p. direct medical costs
of diabetes mellitus in china: annual cost of illness and long-term
projections using a validated diabetes model. ispor asia conference sept 2-4 2012.
sept 4 2012.
tham cc, leung ck, li fc, gerlier l, lamotte m, caputo j, tan r. new formulation of
travoprost reduces dry eye occurrence and costs in glaucoma patients:
model-based results for hong kong. ispor asia conference sept 2-4 2012. pss5. sept
3 2012
gerlier l, lamotte m, caputo j, tan r. the cost-effectiveness of travoprost
preserved with polyquad® in newly treated open-angle glaucoma patients in
7 asian countries. ispor asia conference sept 2-4 2012. pss4. sept 3 2012.
gerlier l, lamotte m, caputo j, tan r. medical resource use and associated costs in
open-angle glaucoma in 10 asia-pacific countries. ispor asia conference sept 2-4
2012. pss3. sept 3 2012.
caekelbergh k, lamotte m. evaluation of real life use of sugammadex for decurarization of
neuromuscular blockade in surgical interventions in belgium. ispor europe conference nov 3-7
2012. php87. nov 5 2012.
chevalier p, black cm, lamotte m, crombach j, huismans j, rosiek r, fan t. frequency of
administration of biologics has an impact on treatment decision making. ispor europe conference
nov 3-7 2012. pms58. nov 6 2012.
chevalier p, lamotte m, petit c. cost-effectiveness of ticagrelor in the management of acute
coronary syndromes in belgium. ispor europe conference nov 3-7 2012. pcv64. nov 5 2012.
gerlier l, vellopoulou k, lamotte m, lacey l, carr e. a health economic evaluation of omega-3 acid
ethyl esters 90 in the secondary prevention post-mi. ispor europe conference nov 3-7 2012.
pcv65. nov 5 2012.
lamotte m, chevalier p. the cost of diabetes complications in belgium. ispor europe conference
nov 3-7 2012. pcv32. nov 5 2012.
lamotte m, gerlier l, chevalier p. the burden of diabetes mellitus in belgium: a retrospective
database study. ispor europe conference nov 3-7 2012. pcv19. nov 5 2012.
vandekerckhove s, lamotte m, iannazzo s, chirita o. cost utility analysis of bortezomib in a
biomarker positive subgroup of relapsed and refractory folicular lymphoma. ispor europe
conference nov 3-7 2012. pcn100. nov 6 2012.
vandekerckhove s, holtzer-goor k, van den steen d, van megen y, huijgens p, lamotte m, uyl- de
groot c. cost effectiveness analysis of bendamustine as first line treatment for chronic
lymphocytic leukaemia in the netherlands. ispor europe conference nov 3-7 2012. pcn90. nov 6
2012.
vellopoulou a, van agthoven m, vanderkolk a, lamotte m, cure s, bianic f. the cost-utility of
telaprevir in combination with peginterferon alpha and ribavirin (pr) as compared to the combination
boceprevir with pr and to pr alone in the management of chronic hepatitis c in the netherlands.
ispor europe conference nov 3-7 2012. pin61. nov 5 2012.
mcewan p, foos v, chraibi m, lloyd a, palmer jl, lamotte m, grant d. random number generators
in monte carlo simulation. ispor europe conference nov 3-7 2012. prm50. nov 6 2012.
foos v, mcewan p, lloyd a, palmer jl, lamotte m, grant d. minimum run-time requirements to
reduce monte carlo error in stochastic simulations. ispor europe conference nov 3-7 2012. prm52.
nov 6 2012.
foos v, palmer jl, grant d, lloyd a, lamotte m, mcewan p. long-term validation of the ims core
diabetes model in type 1 and type 2 diabetes. ispor europe conference nov 3-7 2012. prm58. nov
6 2012.
mcewan p, foos v, lloyd a, palmer jl, lamotte m, grant d. correlating cost-effectiveness output
with patient level data input via the ims core diabetes model (cdm). ispor europe conference
nov 3-7 2012. prm54. nov 6 2012.
foos v, mcewan p, lloyd a, palmer jl, lamotte m, grant d. assessing the relationship between the
effect of glycemic control and avoided symptomatic hypoglycemia on quality of life in the management
of type 2 diabetes. ispor europe conference nov 3-7 2012. db1. nov 5 2012.
duran a, spaepen e, lamotte m, gutiérrez l. comparación de agentes estimulantes de
la eritropoyesis (aee) en el tratamiento de la anemia inducida por
quimioterapia en españa. published in congress book of the liv reunión nacional de la
sehh y xxviii congreso nacional de la seth, salamanca 18 - 20 october 2012. nº
definitivo: pb- 216
2011
duran a, spaepen e, lamotte m, walter e, kutikova l, pujol b, annemans l. cost analysis of
anemia treatment with erythropoiesis-stimulating agents in cancer patients receiving chemotherapy.
16th congress of the eahp, vienna march 2011. abstract number ohp016.
k. moeremans, s. sharma, m. lamotte, m. gallagher. health economic consequences of
systemic safety differences between ranibizumab and unlicensed
bevacizumab. poster presented at the 2nd world congress on controversies in ophthalmology
(cophy). catalonia palace of congresses, barcelona, spain, march 3-6, 2011. poster 41.
sharma s, moeremans k, lamotte m, gallagher m. potential safety differences between unlicensed
bevacizumab (avastin®) and ranibizumab (lucentis®) in age-related macular degeneration (amd) - a
health economic perspective. 11 th euretina congress, may 29-29, 2011. london, uk
duran a, spaepen e, lamotte m, walter e, lucioni c, pinheiro b, brosa m, kutikova l, pujol b,
annemans l. cost analysis of anemia treatment with erythropoieses-stimulating agents (esas) in
patients with cancer receiving chemotherapy: a multi-country approach. ispor 16th annual
international meeting; may 21-25, 2011; baltimore, md, usa
chevalier p, lamotte m, malfait m, marciniak a. the incidence and outcome of febrile neutropenia in
different chemotherapy regimens for cancer patients in belgium. ecco congress on september 24,
2011, poster nr. 3.533.
f. nevens, i. colle, p. michielsen, g. robaeys, c. moreno, k. caekelbergh, m.
lamotte, v. wyffels. resource use and cost of hepatitis c related care in
belgium. belgian week of gastroenterology thursday feb 9 2012 a19 125
caekelbergh k, lamotte m, nevens, colle, michielsen, robaeys, moreno c, wyffels v. resource
use and cost of hepatitis c related care in belgium. ispor europe madrid nov 7-9
2011 pgi14.
chevalier p, lamotte m, malfait m, marciniak a. the incidence and outcome of febrile
neutropenia in different chemotherapy regimens for cancer patients in
belgium. europe madrid nov 7-9 2011 pcn7
gerlier l, schlaen r, lorenz k, lamotte m, verboven y, pfeiffer n. glaucoma management
cost as a function of disease stage and treatment changes. europe madrid nov 7-
9 2011. pss19
gerlier l, shlaen r, wolfram c, lamotte m, verboven y. visual field evolution in
glaucoma patients presenting with different disease stages: results from an
observational study. europe madrid nov 7-9 2011. pss5
gerlier l, lamotte m, lorenz k, berdeaux g, verboven y, pfeiffer n. economic outcomes of
glaucoma treatment with prostaglandin eye drops preserved with
polyquad® instead of benzalkonium chloride in germany. europe madrid nov 7-9
2011. pss10
gerlier l, lamotte m, berdeaux g, verboven y, pfeiffer. longer term patient benefits of
polyquad® preservative instead of benzalkonium chloride in prostaglandin
eye drops: a microsimulation model in ocular hypertension and open-angle
glaucoma. europe madrid nov 7-9 2011. pss4
duran a, spaepen e, lamotte m, brosa m, gutierrez l, restovic g, annemans l. cost analysis:
treatment of chemotherapy-induced anaemia with erythropoiesis-stimulating
agents (esas) in spain. europe madrid nov 7-9 2011. pcn33
duran a, spaepen e, lamotte m, lucioni c, kutikova l, pujol b, gozzo m, annemans l. cost
analysis of anemia treatment with erythropoiesis-stimulating agents (esas)
in cancer patients receiving chemotherapy in italy. europe madrid nov 7-9 2011.
pcn34
leeuwenkamp o, chevalier p, lamotte m. evaluation of the clinical and economic
burden of chronic constipation in belgium. europe madrid nov 7-9 2011. pgi13
2010
dratwa m, bogaert a, caekelbergh k, lamotte m, laplante s. the cost of dialysis in belgium. poster
presentation at the xlvii era-edta congress, in munich, germany, (june 25-28, 2010).
akoua-koffi c, lamotte m. does acute gastro enteritis in infants and children impact the quality of
life of parents? a questionnaire survey in the cote d’ivoire (ivory coast)" poster presentation
at the 9th international rotavirus symposium (johannesburg-south africa_2-3 august 2010).
curran d, lamotte m, van kriekinge g. quality of life impact in parents caring for severe
gastroenteritis in children in 7 countries worldwide. ispor asia september 2010, pukhet, thailand.
dratwa m, bogaert am, bouman k, caekelbergh k, lamotte m, s laplante s. les couts de la
dialyse en belgique. poster presentation at 12ème réunion commune des sociétés de
néphrologie et de dialyse - bruxelles september 30 2010.
gerlier l, lamotte m, verboven y. glaucoma disease progression states:
establishing a direct, quantitative link between visual field defects and
utility loss. ispor europe prague november 2010.
caekelbergh k, lamotte m, dratwa m, bogaert am, bouman k, laplante s. resource use and
costs of patients undergoing dialysis in belgium. ispor europe prague november
2010.
chevalier p, lamotte m, leenaerts p. a health economic evaluation of the switch of
erythropoiesis-stimulating agents (esas) in patients with renal failure
undergoing haemodialysis. ispor europe prague november 2010.
chevalier p, lamotte m. an epidemiological evaluation of the incidence of deep
venous thrombosis and pulmonary embolism in patients with hip or knee
replacement surgery and of its impact on the average length of stay. ispor
europe prague november 2010.
chevalier p, lamotte m. an epidemiological evaluation of the impact of
percutaneous coronary interventions on the length of stay and mortality
of patients hospitalized with acute coronary syndromes. ispor europe prague
november 2010.
laplante s, walker dr, caekelbergh k, lamotte m, dratwa m, bogaert am, bouman k. patient
co-morbidities affect the cost of dialysis patients in belgium. ispor europe
prague november 2010.
duran a, spaepen e, lamotte m, walter e, kutikova l, pujol b, annemans l. real-life cost analysis
of anemia treatment with erythropoiesis stimulating agents in cancer patients receiving
chemotherapy. ash conference 2010 december 6. abstract 3811.
2009
moeremans k, lamotte m, witrup-jensen ku, pignone m. the health economic value of aspirin in
the primary prevention of cardiovascular disease in diabetic patients. oral presentation at american
diabetes association congress new orleans 2009, june 6..
lamotte m, maugars y, de vos c, le lay k, taïeb c. health economic comparison of outpatient
management of fibromyalgia before and after diagnosis in five european countries. poster at eular
congress 2009, copenhagen 10-13 of june.
vinereanu d, cinteză m, ţele p, gerlier l, lamotte m. a health-economic evaluation of
highly concentrated and purified omega-3 polyunsaturated fatty acids (n-3
pufas) in the secondary prevention after myocardial infarction (mi) in
romania “the 48th romanian national cardiology congress” 19-22 september 2009, sinaia,
romania.
caekelbergh k, lamotte m, van megen y. management of opioid induced constipation
(oic) in pain patients: a cost of illness study in belgium and the netherlands.
ispor europe paris october 2009. poster pgi 7.
m. lamotte, y. maugars, k. le lay, c. taïeb. health economic comparison of
outpatient management of fibromyalgia before and after diagnosis in five
european countries. ispor europe paris october 2009. poster pms 29.
m. lamotte, y. maugars, k. le lay, c. taïeb. costs avoided by diagnosing fibromyalgia.
ispor europe paris october 2009. poster pms 28.
van den steen d, petit c, lamotte m. the cost-effectiveness of titration to goal
with brand rosuvastatin compared to generic simvastatin in patients with
elevated low-density lipoprotein cholesterol: primary and secondary
prevention in the belgian health care setting. ispor europe paris october 2009.
poster pcv 94.
gerlier l, lamotte m, wille m, dubois d. cost-utility of autologous chondrocytes
implantation using chondrocelect ® in symptomatic knee cartilage damage in
belgium. ispor europe paris october 2009. poster pms 56.
gerlier l, lamotte m, van megen y. treatment of moderate to severe pain with
oxycodone/naloxone to reduce opioid-induced constipation: a cost-utility
analysis in belgium and the netherlands. ispor europe paris october 2009. poster pgi
15.
ramos m., oliveira m.c., barros p.p. estimating mental health production functions: what does
explain the mental health status of the portuguese population. 2009. 11 th portuguese health
economics conference. poster: 680455 (awarded with best poster)
2008
lecomte p, lamotte m, esposito g, annemans l, kotchie r w, munk vc, vincze g. belgian
budget impact analyses of aliskiren (tekturna/rasilez) in hypertension. poster
presented at the ispor 13th annual international meeting – 3-7 may 2008 – presentation code:
pcv26.
van den steen d, van bellinghen la, liwing j, van vlaenderen i, lamotte m, lothgren m,
annemans l. cost-effectiveness of fentanyl its (ionsystm) in post-operative pain management: a
finnish hospital perspective analysis ispor 11th annual european congress 2008, athens,
greece.
van bellinghen la, lamotte m, malfait m a health economic evaluation of the use of
erythropoiesis-stimulating agents (esa) in patients with renal failure treated with heamodialysis
ispor 11th annual european congress 2008, athens, greece.
gerlier l, de vos c, lamotte m, malfait m, poitrinal p. epidemiology of idiopathic thrombocytopenic
purpura in belgium assessed using hospital records. ispor 11th annual european congress 2008,
athens, greece.
gerlier l, lamotte m, van lommel n, wille m, vanlauwe jj. relief of pain and symptoms in knee
cartilage defect is associated with higher sf-36 utility scores: data from a prospective randomized
trial of chondrocelect® ispor 11th annual european congress 2008, athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. costs avoided by diagnosing
fibromyalgia in spanish patients. ispor 11th annual european congress 2008, athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. health economic evaluation of
outpatient management of fibromyalgia in spain. ispor 11th annual european congress 2008,
athens, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. costs avoided by diagnosing
fibromyalgia in french patients ispor 11th annual european congress, athens 2008, greece.
lamotte m, maugars y, de vos c, girard l, le lay k, taieb c. health economic evaluation of
outpatient management of fibromyalgia in france ispor 11th annual european congress
2008, athens, greece.
caekelbergh k, lamotte m, muchada jp. management of herpes zoster (hz) and post-herpetic
neuralgia (phn) in belgium: a cost of illness study. ispor 11th annual european congress 2008,
athens, greece.
strens d, lamotte m. medical resource consumption related to the treatment of irinotecan refractory
advanced colorectal cancer patients. ispor 11th annual european congress 2008, athens, greece.
maugars y, lamotte m, van vlaenderen i, le lay k, taieb c. paramedical or alternative
treatments and associated costs for the management of fibromyalgia in
france. ispor 11th annual european congress 2008, athens, greece.
maugars y, lamotte m, van vlaenderen i, le lay k, taieb c. outpatient medical
management of fibromyalgia in france compared to the united kingdom. ispor
11th annual european congress 2008, athens, greece.
van bellinghen la, van den steen d, liwing j, lamotte m, lothgren m, annemans l. cost-
effectiveness of fentanyl its (ionsystm) in post-operative pain management: a swedish hospital
perspective analysis. sfai 2008 vetenskap congress, uppsala, sweden.
2007
dendale p, hansen d, berger j, vaes j, reenaers v, lamotte m. long term effects and cost
effectiveness of multidisciplinary cardiac rehabilitation after percutaneous coronary intervention.
poster at annual congress of belgian society of cardiology february 2007.
esposito g, lamotte m, annemans l, bracco a. a cost-consequence analysis of
darbepoetin alfa administered every 3 weeks (q3w_da) compared to weekly
epoetin alfa (qw_ea) or epoetin beta (qw_eb) in patients with chemotherapy-
induced anemia (cia): the italian case. ispor 10 th annual european congress. contributed
poster presentations session ii - monday, 22 october. value in health 2007; volume 10, issue 6.
a324 - pcn8
van bellinghen la, esposito g, lamotte m, bracco a, goertz a, annemans l. a cost-
consequence analysis of darbepoetin alfa administered every 3 weeks
(q3w_da) compared to weekly epoetin alfa (qw_ea) or epoetin beta (qw_eb) in
patients with chemotherapy-induced anemia (cia): the german case. ispor 10 th
annual european congress. contributed poster presentations session ii - monday, 22 october. value
in health 2007; volume 10, issue 6. a328 - pcn19
demarteau n, braeckman j, michielsen d, sweet a, zyczynski t, lamotte m. a health economic
evaluation of hexvix as adjunct to standard white light cystoscopy in the
management of superficial bladder cancer. ispor 10 th annual european congress.
contributed poster presentations session ii - monday, 22 october. value in health 2007; volume 10,
issue 6. a328 - pcn 21
2006
lamotte m, annemans l, evers t, kubin m, hu s. a health economic evaluation of
aspirin in the primary prevention of cardiovascular disease. 2 nd asia-pacific
congress of the international society of pharmacoeconomics and outcome research – shanghai,
china, march 5-7 2006. pcv4.
mark lamotte, lieven annemans, marie-christine herregods, jean-claude daubresse, georges
michel, guy vandenhoven, eugène vissers. the cost-effectiveness of rosuvastatin and atorvastatin in
the primary prevention of cardiovascular disease based on the discovery belux-study. poster at
europrevent congress athens may 11-13 2006, poster id: 52.
lamotte m, annemans l, schockaert b the impact of dose increase on the cost-
effectiveness of statins. ispor 11th annual international meeting may 20-24, 2006 marriott
philadelphia, philadelphia, pa. pcv27
lamotte m, annemans l, evers t, kubin m, hu s. a health economic evaluation of
aspirin in the primary prevention of cardiovascular disease. ispor 2nd asia-
pacific conference to be held at the worldfield convention hotel, shanghai, china, 5-7 march 2006
lamotte m, annemans l, van loy r, koch w. a cost-effectiveness analysis of
olmesartan in the treatment of arterial hypertension 9th european congress of
the international society of pharmacoeconomics and outcome research – copenhaguen, denmark,
october 28-31 2006. value in health 2006 pcv34
lamotte m, annemans l, siebert m a health economic evaluation of concomitant
surgical ablation for atrial fibrillation 9th european congress of the international
society of pharmacoeconomics and outcome research – copenhaguen, denmark, october 28-31
2006. value in health 2006 pcv36
lamotte m, annemans l, raskin a, hansen d, dendale p. a cost-effectiveness analysis
of cardiac rehabilitation after percutaneous coronary interventions 9th
european congress of the international society of pharmacoeconomics and outcome research –
copenhaguen, denmark, october 28-31 2006. value in health 2006 pcv40
strens d, lamotte m, fassotte c, annemans l. burden of illness of abdominal obesity:
a retrospective chart review. monday, 30 october 2006 08:00 - 19:30 at the ispor 9th
annual european congress, 28-31 october 2006, radisson sas falconer hotel & conference
center, copenhagen, denmark. value in health 2006.
2005
m lamotte, l annemans, k el ouagari, a gnanasakthy, zm khan: managing post-mi patients with an
angiotensin ii receptor blocker: a health economic evaluation of real-life long-term consequences.
esc congress, stockholm, 6 sept 2005: poster number 3630.
m lamotte, l annemans, a gnanasakthy, zm k. a health-economic evaluation of the
real life long-term consequences of valsartan in the management of post mi
patients. 10 th international congress of the international society of pharmacoeconomics and
outcome research - waschington dc, us, may 14-18 2005. value in health 2005
ethgen o, lamotte m, annemans l. health economic evaluation of bivalirudin in the management of
patients undergoing percutaneous coronary intervention in belgium. 8th european congress of the
international society of pharmacoeconomics and outcome research – florence, italy, november 6-8
2005. value in health 2005.
lamotte m, annemans l, schockaert b. a cost-effectiveness analysis of candesartan
in the treatment of chronic heart failure 8th european congress of the international
society of pharmacoeconomics and outcome research – florence, italy, november 6-8 2005. value
in health 2005 cv3
lamotte m, annemans l, evers t and kubin m. a cost-effectiveness analysis of low-
dose aspirin in the primary prevention of cardiovascular disease in four
european countries. 8th european congress of the international society of
pharmacoeconomics and outcome research – florence, italy, november 6-8 2005. value in health
2005 pcv 33
2004
palmer aj, annemans l, roze s, lamotte m, rodby ra, ritz e. health economic consequences of
irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in germany.
dtsch med wochenschr 2004; 129: 13-8.
lamotte m, cleemput i, annemans l. a health economic evaluation of 6-months alfuzosin treatment
in the management of acute urinary retention. value in health 2004; 7: 800.
lamotte m, annemans l, evers t, kubin m. a health economic evaluation of aspirin in the primary
prevention of cardiovascular disease. value in health 2004; 7: 637. best podium presentation
award winner.
palmer aj, annemans l, roze s, lamotte m, rodby ra, bilous rw. an economic evaluation of the
irbesartan in diabetic nephropathy trial (idnt) in a uk setting. j hum hypertens. 2004 apr 29
2003
palmer aj, annemans l, roze s, lamotte m, rodby ra, cordonnier dj. an economic evaluation of
irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-
effectiveness of irbesartan in diabetic nephropathy trial (idnt) in the belgian and french settings.
nephrol dial transplant. 2003 oct;18(10):2059-2066.
palmer aj, annemans l, roze s, lamotte m, lapuerta p, gabriel s, chen r, carita p,villadary i,
rodby r, de zeeuw d, parving hh. irbesartan is projected to be cost and life saving
in the french setting for treatment of patients with type 2 diabetes,
hypertension, and microalbuminuria. value in health 2003; 6: 615.
lamotte m, annemans l, de keyser p. a health economic evaluation of n-3
polyunsaturated fatty acids (pufa) in the secondary prevention after mi. value
in health 2003; 6: 629.
lamotte m, caekelbergh k, annemans l, de keyser p. assessment of the cost of
cardiovascular death. value in health 2003; 6: 658 (poster).
palmer aj, borsos k, roze s, annemans l, lamotte m, rodby r,valentine wj. irbesartan is
cost-saving compared to amlodipine and standard blood pressure treatment
in patients with type 2 diabetes, hypertension and nephropathy in hungary.
value in health 2003; 6: 662 (poster).
magaz s, badia x, annemans l, lamotte m. cost-effectiveness analysis of coronary
revascularisation techniques available for the treatment of ischaemic heart
disease .value in health 2003; 6: 668 (poster).
lamotte m, massaer k,vranckx k, annemans l. a cost analysis of alfuzosin in the
management of acute urinary retention. value in health 2003; 6: 703 (poster).
2002
lamotte m, annemans l, de jong p: drug eluting stents in coronary artery disease: assessment of
outcomes and cost-effectiveness. eur heart j 2002; 23 (suppl): 137: 810 + oral presentation at esc
2002.
marchetti m, tarricone r, lamotte m, annemans l, de jong p: cost-effectiveness and budget impact
of the sirolimus-eluting stent in the stent era. value in health 2002; 5: 457: hs1 + oral presentation at
ispor 2002.
palmer aj, annemans l, roze s, lamotte m, guilhaume c, gabriel s, carita p, chen r, simon t,
rodby r, cordonnier dj: the health-economic impilications of the irbesartan in diabetic nephropathy
trial (idnt) in france and belgium. value in health 2002; 5: 546: pdb4 + poster at ispor 2002.
2001
annemans l, lamotte m, huybrechts m. issues and problems encountered in models
on prevention of deep venous thrombosis (dvt) ispor 6th annual international
meeting may 20-23, 2001. ww3
lamotte m, annemans l, peys f: gezondheidseconomische aspecten van interventies in de
preventie en behandeling van diabetes in belgië. bige-briefing maart 2001; 1-8.
lamotte m, annemans l, peys f: ethische en economische aspecten van de diabetesvoet in belgië.
bige-briefing september 2001; 6-8.
m. lamotte, l. annemans, a. lefever, m. nechelput, j. masure: orlistat in obese type 2 diabetic
patients: assessment of long-term outcomes and cost-effectiveness. value in health 2001; 4 (6): 408
(cv5) + oral presentation at ispor 2001.
2000
l. annemans, m. lamotte, m. keech, k. wilson: health economic model to describe the current and
expected burden of copd. value in health 2000; 3 (5); 328 (prs 4).
1996
m. lamotte, l. lasser, p. dendale, a. ae rts, m. noppen, p. melis, p. block: influence of
sympathicolysis of d2-d3 on rate and blood pressure in patients with hyperhidrosis. oral poster
presentation on annuel scientific meeting of the belgium society of cardiology; 31 jan. ‘97 + abstract
in acta cardiologica. vol. 51, 6, 1996: 568-9.
a. aerts, p. dendale, m. lamotte, l. lasser, p. block: influence of tilt duration on diagnostic value in
sublingual nitrate stimulated head up tilt testing. oral poster presentation on annuel scientific
meeting of the belgium society of cardiology; 31 jan. ‘97 + abstract in acta cardiologica. vol. 51, 6,
1996: 586.
